Last reviewed 2026-04-19 · How we verify

donor-derived CIK cells

A.O. Ospedale Papa Giovanni XXIII · Phase 1 active Biologic

donor-derived CIK cells is a Biologic drug developed by A.O. Ospedale Papa Giovanni XXIII. It is currently in Phase 1 development.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	donor-derived CIK cells
Sponsor	A.O. Ospedale Papa Giovanni XXIII
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

donor-derived CIK cells CI brief — competitive landscape report
donor-derived CIK cells updates RSS · CI watch RSS
A.O. Ospedale Papa Giovanni XXIII portfolio CI

Frequently asked questions about donor-derived CIK cells

What is donor-derived CIK cells?

donor-derived CIK cells is a Biologic drug developed by A.O. Ospedale Papa Giovanni XXIII.

Who makes donor-derived CIK cells?

donor-derived CIK cells is developed by A.O. Ospedale Papa Giovanni XXIII (see full A.O. Ospedale Papa Giovanni XXIII pipeline at /company/a-o-ospedale-papa-giovanni-xxiii).

What development phase is donor-derived CIK cells in?

donor-derived CIK cells is in Phase 1.

Manufacturer: A.O. Ospedale Papa Giovanni XXIII — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing